top of page

2 days ago

ASH 2024: Disc Medicine's CEO shares an update on three programs, including an oral presentation for an anti-anemia antibody for patients with myelofibrosis and potentially beyond in the future

John Quisel shares an update on ASH data for DISC-0974, bitopertin, and DISC-3405.

Recent Posts

Seattle based Umoja Biopharma is a pioneer of in vivo CAR-T cell engineering. CEO Andrew Scharenberg describes the technical innovations they have come up with to help make it succeed

ASH 2024: France's MaaT Pharma presented early access data at ASH for its microbiome based treatment for GvHD - a formal study will read out early next year

ASH 2024: Nurix Therapeutics' CEO Arthur Sands talks BTK degradation vs inhibition and the company's broader pipeline of degraders

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Klein Hersh is a precision executive search firm with over 25 years of proven success partnering with clients to deliver the visionary leaders shaping the future of life sciences and healthcare. We believe that the innovation behind a healthier world starts with bringing the best and brightest minds together. Our experienced team of dedicated experts is deeply immersed in every facet of pharma, biotech, and healthcare, and has developed trusted relationships with far-reaching talent networks.

Visit Klein Hersh

bottom of page